Traders assign a 94.5% implied probability against a new COVID variant of concern before 2027 because global surveillance shows no escalation to VOC status despite ongoing Omicron sublineage circulation. WHO and ECDC tracking as of July 2026 lists only JN.1 as a variant of interest and several sublineages such as NB.1.8.1, XFG, BA.3.2, and PQ.16.1.1 as variants under monitoring, none of which have demonstrated the transmissibility, severity, or immune-escape traits required for higher classification. COVID activity remains low in the United States and many regions through mid-August 2026, with updated 2026-2027 vaccines targeting XFG reflecting gradual evolution rather than disruptive change. Population immunity from prior infections and vaccinations continues to limit the potential for any subvariant to meet VOC criteria in the remaining months of 2026.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$244,719 Vol.
$244,719 Vol.
Oui
$244,719 Vol.
$244,719 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Traders assign a 94.5% implied probability against a new COVID variant of concern before 2027 because global surveillance shows no escalation to VOC status despite ongoing Omicron sublineage circulation. WHO and ECDC tracking as of July 2026 lists only JN.1 as a variant of interest and several sublineages such as NB.1.8.1, XFG, BA.3.2, and PQ.16.1.1 as variants under monitoring, none of which have demonstrated the transmissibility, severity, or immune-escape traits required for higher classification. COVID activity remains low in the United States and many regions through mid-August 2026, with updated 2026-2027 vaccines targeting XFG reflecting gradual evolution rather than disruptive change. Population immunity from prior infections and vaccinations continues to limit the potential for any subvariant to meet VOC criteria in the remaining months of 2026.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes